More than 12,000 university jobs lost across UK
More than 12,000 university jobs have been cut across the UK in the past year, according to new analysis from the University and College Union (UCU), ...
Radionuclide therapy using the radioactive element terbium shows promising potential in treating lymphoma, according to recent experimental results from the Paul Scherrer Institute (PSI) in collaboration with Inselspital – Bern University Hospital.
Elisa Rioja-Blanco and Martin Béhé are jointly conducting research at the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. The researchers are now refining this type of therapy in order to carry out clinical trials.
Every year, almost 2,000 people in Switzerland are diagnosed with lymphoma, and about 570 of them die from the disease. Researchers at PSI’s Center for Radiopharmaceutical Sciences are now proposing a new therapy that could soon increase the chances of survival for many of those affected: radioimmunotherapy with the nuclide terbium-161.
“The radioactive isotope terbium-161 is attached to an antibody and injected into the bloodstream of the patient,” explains Martin Béhé from the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. This antibody latches onto a structure in the body that is particularly common in lymphoma cells: the CD30 receptor. “This brings the radioactive terbium directly to the site of the tumour to kill the cancer cells with its radioactive radiation.” Healthy organs in the body are spared, on the other hand.
In almost a third of all lymphoma patients, the tumour cells produce the CD30 receptor – in these patients the new treatment could be applied. The same is true of T-cell lymphomas, in which the T-lymphocytes of the immune system become cancerous – a disease that has until now been difficult to treat.
Radionuclide therapy is already well established in clinical practice. Hospitals currently carry out this form of cancer treatment with a different radioactive substance: the nuclide lutetium-177. This is used to treat prostate cancer and tumours arising from hormone-producing cells. Radioactive lutetium decays to produce high-energy, high-velocity electrons, called beta particles, which combat larger tumours effectively.
However, individual tumour cells and small clusters of cancer cells elude treatment with lutetium-177 and can lead to a recurrence of the disease. This makes this form of radionuclide therapy unsuitable for lymphoma. In this type of cancer, some of the tumour cells circulate in the bloodstream rather than existing as a larger, localisable tumour.
Terbium-161 has a decisive advantage over lutetium-177: in addition to beta particles, it also emits conversion and Auger electrons. “This radiation has a range of less than one micrometre, or one thousandth of a millimetre. This is the size of a tumour cell,” explains Martin Béhé. Hence, terbium-161 acts on its immediate surroundings, making it particularly suitable for the targeted treatment of smaller tumours.
“Terbium-161 fires more precise bullets, so to speak,” explains Elisa Rioja-Blanco, also from the Center for Radiopharmaceutical Sciences and first author of the study. Even individual cancer cells in the blood could be eliminated without causing severe side effects. “We can also catch small tumour foci that doctors may not even be aware of at the time.”
The isotope has a half-life of 6.9 days, which means that its effect is halved every 6.9 days. This is an advantage for radionuclide therapy: after manufacturing the drug, it can be transported to a hospital without losing too much of its activity on the way. On the other hand, the radiation level decreases rapidly after treatment within a reasonable period of time.
A powerful weapon against cancer cells
The PSI researchers led by Martin Béhé and Elisa Rioja-Blanco produced the active substance, consisting of terbium-161 and an antibody against the CD30 receptor, themselves at PSI. They then tested it in the laboratory on three types of cancer cells that produce CD30 receptors. They found that – depending on the type of cell – the substance was 2 to 43 times as effective at killing the cancer cells than the analogous substance using lutetium-177. Further experiments have shown that this is because the terbium-based drug caused more severe damage to the DNA in the cancer cell, which the cell itself is unable to repair.
The researchers then tested the drug on mice suffering from cancer. “This shows us where the substance accumulates in the body and whether it actually reaches tumours,” explains Elisa Rioja-Blanco. The substance was indeed preferentially absorbed by the tumour tissue. On average, mice treated with terbium-161 survived twice as long as their counterparts injected with a lutetium-177 drug. Some of the mice even ended up completely cancer-free after the treatment.
On the way to clinical trials
Terbium-161 is already being tested as an anti-cancer drug in several clinical trials – the PSI researchers have now for the first time scrutinised it as a potential treatment for lymphoma. “Our results are a good indication that the substance could also prove to be effective against lymphoma in humans,” says Elisa Rioja-Blanco. Clinical studies will hopefully soon show whether this is indeed the case.
The Lymphoma Challenge, organised by ETH Zurich, is providing financial support for the project. The team has now secured follow-on funding from Innosuisse to further investigate and optimise the drug so that it can be commercialised and tested in humans in the future.
Video from the USGS (United States Geological Survey) showed on Friday (19 September) the Kilauea volcano in Hawaii erupting and spewing lava.
At least eight people have died and more than 90 others were injured following a catastrophic gas tanker explosion on a major highway in Mexico City’s Iztapalapa district on Wednesday, authorities confirmed.
At least 69 people have died and almost 150 injured following a powerful 6.9-magnitude earthquake off the coast of Cebu City in the central Visayas region of the Philippines, officials said, making it one of the country’s deadliest disasters this year.
Authorities in California have identified the dismembered body discovered in a Tesla registered to singer D4vd as 15-year-old Celeste Rivas Hernandez, who had been missing from Lake Elsinore since April 2024.
A powerful 7.4-magnitude earthquake struck off Russia’s Kamchatka Peninsula on 13 September with no tsunami threat, coming just weeks after the region endured a devastating 8.8-magnitude quake — the strongest since 1952.
Indian police have arrested the owner of Sresan Pharmaceutical Manufacturer, the cough syrup company linked to the deaths of at least 19 children in the central state of Madhya Pradesh, a senior police officer told Reuters on Thursday.
More than 200 health facilities in war-hit eastern Congo have run out of medicines due to widespread looting and supply chain disruptions during fighting this year, the International Committee of the Red Cross (ICRC) said on Wednesday.
Indian authorities have launched a manslaughter investigation after at least 14 children died from a toxic cough syrup in Madhya Pradesh, raising fresh concerns over the country’s pharmaceutical safety.
U.S. President Donald Trump’s decision to impose 100% tariffs on branded and patented pharmaceuticals manufactured abroad poses a serious threat to Germany’s pharmaceutical sector, according to the Berlin-based industry group Verband Forschender Arzneimittelhersteller (vfa).
A flock of Canadian ostriches set to be culled, after two dead birds tested positive for avian flu, has been granted a last-minute stay of execution from Canada's highest court - for now.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment